Did an iceberg just wallop into Omeros (OMER) stock? The drug maker’s shares are plunging at breakneck speed of almost 20%.
By Richard Robinson Many Americans are optimistic about achieving a comfortable retirement. They fund their 401(k) or IRA in hopes of accumulating a nest …
Omeros (NASDAQ:OMER) shares are soaring today after the drug maker reported quarterly results, and there’s a lot more fuel in the tank to …
With new hope for a two-year reimbursement extension for Omidria, Jason McCarthy now bets on 58% in return potential for the stock.
H.C.
A lengthy short-seller research report has shares of Omeros in free fall.
OMER shares may be seeing a pullback today, but this bull believes the drug maker has a standout product profile in its kidney asset that can save patient lives.
So what to make of Omeros Corporation’s (NASDAQ:OMER) latest success? This morning, the drug maker announced that it has reached an agreement with …
Maxim’s Jason Kolbert is keeping his focus peeled to the Omeros pipeline, even though he welcomes the FDA victory for Omidria.
The fundamentals behind Omeros’ (NASDAQ:OMER) eye drug Omidria continue to get better, but Cantor analyst Elemer Piros believes the company still needs to remove …
